DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Crenezumab
Crenezumab
WO 2015/120233 Al 13 August 2015 (13.08.2015) P O P C T
Treatment of Alzheimer's Disease and Blood–Brain Barrier Drug Delivery
Passive Immunotherapy for Alzheimer's Disease: What Have We
Tables-Of-Phase-3-Mabs.Pdf
Structure of Crenezumab Complex with Aβ Shows Loss of Β-Hairpin
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Monoclonal Antibodies As Neurological Therapeutics
ALZHEIMER's DISEASE UPDATE on CURRENT RESEARCH Lawrence S
Development of the Clinical Candidate PBD-C06, a Humanized Pglu3-Aβ-Specific Antibody Against Alzheimer's Disease with Reduced Complement Activation
INN Working Document 05.179 Update 2011
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
What Have We Learned from Aducanumab?
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
(INN) for Biological and Biotechnological Substances
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Another Alzheimer's Failure: Crenezumab Bites the Dust
Introduction
April 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Top View
Full Disclosures
Diabetic Macular Edema (DME): High Unmet Medical Need Significant Global Burden Due to Vision Loss
Anti-Amyloid-Β Monoclonal Antibodies for Alzheimer's Disease
Research Advocacy Training
Gantenerumab Reduces Amyloid-Β Plaques in Patients with Prodromal
Anti-Aβ Antibody Target Engagement: a Response to Siemers Et Al
Moving Beyond the Aβeta Hypothesis of Alzheimer's Disease
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Early Diagnosis and Treatment of Alzheimer's Disease
(INN) for Biological and Biotechnological Substances
WO 2018/231759 Al 20 December 2018 (20.12.2018) W !P O PCT
An in Vitro Paradigm to Assess Potential Anti-Aβ Antibodies for Alzheimer’S Disease
A Phase 2 Randomized Trial of Crenezumab in Mild to Moderate Alzheimer Disease
Computational Analysis for the Rational Design of Anti-Amyloid Beta (A ) Antibodies
Annual Report 2014
A Phase III, Multicenter, Randomized, Double-Blind, Placebo